These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 23846924)

  • 1. New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma.
    Ramfidis VS; Syrigos KN; Saif MW
    JOP; 2013 Jul; 14(4):344-6. PubMed ID: 23846924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward.
    Ramfidis VS; Psyrri A; Syrigos KN; Saif MW
    JOP; 2014 Jul; 15(4):286-8. PubMed ID: 25076321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The winning formulation: the development of paclitaxel in pancreatic cancer.
    Ma WW; Hidalgo M
    Clin Cancer Res; 2013 Oct; 19(20):5572-9. PubMed ID: 23918602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-line treatment for pancreatic cancer.
    Kaddis N; Saif MW
    JOP; 2014 Jul; 15(4):344-7. PubMed ID: 25076339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical studies in the second line setting of advanced pancreatic cancer: are we making any progress?
    Ramfidis VS; Strimpakos AS; Syrigos KN; Saif MW
    JOP; 2012 Jul; 13(4):358-60. PubMed ID: 22797389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advancements in the management of pancreatic cancer: 2013.
    Saif MW
    JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Nab-paclitaxel].
    Lopez-Trabada Ataz D; Dumont S; André T
    Bull Cancer; 2015 Jun; 102(6):568-76. PubMed ID: 26008630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma.
    Rubinson DA; Wolpin BM
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):761-76. PubMed ID: 26226909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival.
    Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P; McGuire JR; Iglesias J
    Clin Breast Cancer; 2012 Oct; 12(5):313-21. PubMed ID: 22728026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second line therapy for advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
    Brus C; Saif MW
    JOP; 2010 Jul; 11(4):321-3. PubMed ID: 20601802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer.
    Hosein PJ; de Lima Lopes G; Pastorini VH; Gomez C; Macintyre J; Zayas G; Reis I; Montero AJ; Merchan JR; Rocha Lima CM
    Am J Clin Oncol; 2013 Apr; 36(2):151-6. PubMed ID: 22307213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
    Novarino A; Satolli MA; Chiappino I; Giacobino A; Bellone G; Rahimi F; Milanesi E; Bertetto O; Ciuffreda L
    Am J Clin Oncol; 2009 Feb; 32(1):44-8. PubMed ID: 19194124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.
    Dranitsaris G; Cottrell W; Spirovski B; Hopkins S
    J Oncol Pharm Pract; 2009 Jun; 15(2):67-78. PubMed ID: 19036903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.
    Von Hoff DD; Goldstein D; Renschler MF
    N Engl J Med; 2014 Jan; 370(5):479-80. PubMed ID: 24476438
    [No Abstract]   [Full Text] [Related]  

  • 15. Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.
    Saltz LB; Bach PB
    N Engl J Med; 2014 Jan; 370(5):478. PubMed ID: 24476439
    [No Abstract]   [Full Text] [Related]  

  • 16. Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.
    Sahoo RK; Kumar L
    N Engl J Med; 2014 Jan; 370(5):478-9. PubMed ID: 24476440
    [No Abstract]   [Full Text] [Related]  

  • 17. FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer.
    Ghosn M; Farhat F; Kattan J; Younes F; Moukadem W; Nasr F; Chahine G
    Am J Clin Oncol; 2007 Feb; 30(1):15-20. PubMed ID: 17278889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe hyponatremia caused by nab-paclitaxel-induced syndrome of inappropriate antidiuretic hormone secretion: A case report in a patient with metastatic pancreatic adenocarcinoma.
    Neuzillet C; Babai S; Kempf E; Pujol G; Rousseau B; Le-Louët H; Christophe Tournigand
    Medicine (Baltimore); 2016 Jun; 95(26):e4006. PubMed ID: 27368013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
    Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
    J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study.
    Robert N; Krekow L; Stokoe C; Clawson A; Iglesias J; O'Shaughnessy J
    Breast Cancer Res Treat; 2011 Jan; 125(1):115-20. PubMed ID: 20945091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.